


PHARMACEUTICAL 2022

RespireRx Pharmaceuticals Inc. Rank 409 of 475







PHARMACEUTICAL 2022

RespireRx Pharmaceuticals Inc. Rank 409 of 475

The relative strengths and weaknesses of RespireRx Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RespireRx Pharmaceuticals Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 1,269% points. The greatest weakness of RespireRx Pharmaceuticals Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 216% points.

The company's Economic Capital Ratio, given in the ranking table, is -456%, being 180% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	209
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,922
Liabilities, Non-Current	294
Other Assets	0
Other Compr. Net Income	0
Other Expenses	725
Other Liabilities	0
Other Net Income	139
Property and Equipment	0
Research and Development	702
Revenues	0
Selling, General and Administrative Expense	1,857

Output Variable	Value in 1000 USD
Assets	209
Liabilities	10,216
Expenses	3,284
Stockholders Equity	-10,008
Net Income	-3,145
Comprehensive Net Income	-3,145
Economic Capital Ratio	-456%

